BIO-TECHNE Corp (TECH) Stock
4 members of Congress disclosed 15 trades in TECH since 2015: 6 purchases and 9 sales, most recently April McClain Delaney (sale, Apr 8, 2026). 7 of the hedge funds AlphaScala tracks reported TECH in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Maverick Capital's at $108.49M.
Which members of Congress traded BIO-TECHNE Corp (TECH)?
Most recent: April McClain Delaney (sale, Apr 8, 2026); records start Feb 13, 2015.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| April McClain Delaney D-MD · House | 2026-04-08 | sale | $1k – $15k |
| April McClain Delaney D-MD · House | 2026-03-26 | partial sale | $1k – $15k |
| April McClain Delaney D-MD · House | 2026-02-24 | partial sale | $1k – $15k |
| April McClain Delaney D-MD · House | 2026-01-28 | partial sale | $1k – $15k |
| April McClain Delaney D-MD · House | 2025-12-05 | purchase | $1k – $15k |
| April McClain Delaney D-MD · House | 2025-12-02 | purchase | $1k – $15k |
| April McClain Delaney D-MD · House | 2025-10-22 | purchase | $1k – $15k |
| April McClain Delaney D-MD · House | 2025-08-01 | partial sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 2, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
See all TECH political trades →Which hedge funds own TECH?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Maverick Capital Lee Ainslie | 1.54M | $108.49M | -68% |
| Millennium Management Israel Englander | 989K | $69.88M | NEW |
| Citadel Ken Griffin | 966K | $68.24M | +2126% |
| Soros Fund Management George Soros (founder) | 535K | $37.83M | NEW |
| D.E. Shaw David Shaw | 228K | $16.14M | NEW |
| Marshall Wace | 89K | $6.32M | -4% |
| Bridgewater Associates Ray Dalio | 27K | $1.89M | +348% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →TECH price chart
Powered by TradingViewWhat does BIO-TECHNE Corp do?
Bio-Techne Corporation is a global developer, manufacturer and supplier of high-quality reagents, analytical instruments, and precision diagnostics serving the research, diagnostic, and bioprocessing markets worldwide. The company operates through two primary segments: protein sciences, which develops biological reagents including cytokines, growth factors, antibodies, and cell selection technologies; and diagnostics and spatial biology, which provides diagnostic reagents, molecular diagnostics, and spatial biology products. Bio-Techne maintains an extensive catalog of over 500,000 products, with approximately 95% manufactured in-house. Its portfolio includes flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Asuragen, and Tocris Bioscience, serving academic research institutions, pharmaceutical and biotechnology companies, clinical diagnostic laboratories, and government agencies. Headquartered in Minneapolis, Minnesota, the company operates manufacturing facilities, research centers, and customer support offices across North America, Europe, and Asia-Pacific, generating significant revenue from the United States while maintaining a strong international presence. Bio-Techne's reputation for high-quality proteomic reagents and instruments enables it to maintain strong margins and cash flow while supporting scientific discovery and clinical breakthroughs.